Revenue : 000,000 M USD
Finance : 000,000 M USD
Earning Cap : 000,000 M USD
Invest : 000,000 M USD
R & D : 0000 People
Growth : 00% AGR



General Introduction Aier Ophthalmology Hospital Group Co., Ltd. is an ophthalmic medical group with hospital scale and high-quality medical capabilities in China and globally. It has three listed companies in mainland China, Europe, and Southeast Asia (China A-share: Aier Ophthalmology, 300015; Spain: CBAV; Singapore: 40T). Currently, there are 816 ophthalmic hospitals and centers worldwide, including 698 in mainland China, 8 in Hong Kong, 1 in the United States, 96 in Europe, and 13 in Southeast Asia. In 2022, the annual outpatient volume in mainland China exceeded 16 million people and the surgical volume exceeded 1.12 million units. (Note: As of June 2023, the number of institutions under Aier Ophthalmology has been updated.) Aier Ophthalmology always adheres to domestic development as the main line, and promotes both domestic and international efforts to make progress together. In the process of development, we are committed to introducing and absorbing internationally synchronized ophthalmic technology and medical management concepts, with a development strategy of specialization, scale, and scientificity, to promote the development of China's ophthalmic medical industry. Through continuous practice and on the basis of fully absorbing international high-quality medical management experience, we have successfully explored a set of ophthalmic hospital chain management models that adapt to China's national conditions and market environment - "graded chain". We fully leverage the advantages of talent, technology, and management, improve the quality of diagnosis and treatment, improve medical services, and optimize doctor-patient communication. Scientific research innovation and talent cultivation are the cornerstone of long-term development. Aier Ophthalmology continuously increases research investment, vigorously supports the development of cutting-edge and original ophthalmic academic research, and fully promotes the eye health ecosystem strategy on a global platform. Since the joint establishment of Aier Ophthalmology and Central South University in 2013, Aier Ophthalmology College of Central South University has officially launched innovative exploration of school enterprise cooperation. It has successively promoted strategic cooperation with well-known universities such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, Sichuan University, etc., fully leveraging the unique advantages of enterprises and universities, in hospital co construction, talent cultivation, and faculty building We will engage in in-depth cooperation in teaching and research fields, collaborate to build an ophthalmic medicine teaching and research platform, and work together to create a model of "famous schools+enterprises", cultivating more outstanding ophthalmic medicine talents for society, truly contributing wisdom and strength to the innovative development of ophthalmology and visual science in China. On this basis, Aier Ophthalmology continues to build a three-dimensional scientific research platform, and has so far established an innovative integrated science, education, and research platform with "eight institutes, two stations, two bases, and three centers" nationwide. Eight Institutes: Ai'er Ophthalmology Research Institute, Ai'er Ophthalmology Research Institute, Ai'er Corneal Disease Research Institute, Ai'er Refraction Research Institute, Ai'er Retina Research Institute, Ai'er Glaucoma Research Institute, Ai'er Cataract and Artificial Lens Research Institute, and Wuhan Ai'er Ophthalmology Research Institute. Approved to establish "two stations": National Postdoctoral Research Workstation and Hunan Provincial Academician and Expert Workstation; "Second Base": Hunan Province Eye and Optometry International Technology Cooperation Base and Hunan Province "Haizhi Plan" Work Base; "Three Centers": Hunan Provincial Eye and Optometry Engineering Technology Research Center, Hunan Provincial Clinical Medical Research Center for Eye Surface Diseases, and Hunan Provincial Enterprise Technology Center; Jointly build innovative platforms such as the "Aier Ophthalmology Institute of Chinese Academy of Sciences Digital Ophthalmology Joint Laboratory". Ten years after its listing, Aier Ophthalmology has set three strategic goals under the guidance of "innovation driven, technology oriented". The first goal is to extend the medical service network of Aier Ophthalmology to a wide range of urban and rural counties, so that people can enjoy high-quality and accessible ophthalmic medical services at their doorstep, and promote the Healthy China strategy. The second goal is to build world-class and national ophthalmic medical centers, effectively improve China's ophthalmic medical technology level, and catch up with and surpass the world's advanced level. The third goal is to promote the progress of human ophthalmology and visual science through a global layout and comprehensive coordinated development of medicine, education, research, production, and investment. In the course of 19 years of entrepreneurial development, Aier Ophthalmology has condensed and cultivated a group of experienced, pioneering and innovative management teams, as well as a team of ophthalmologists and doctors with excellent medical skills and rigorous treatment. As of now, the total number of employees of the Aier Eye Hospital Group and its subsidiaries worldwide has exceeded 50000, including more than 9000 ophthalmologists and optometrists (including overseas), including a large number of doctoral supervisors, master's supervisors, doctoral students, postdoctoral fellows, scholars studying in Europe and America, and core experts with rich clinical experience. The development and growth of Aier Ophthalmology has always been based on the original intention and mission of "enabling everyone, regardless of poverty or wealth, to enjoy the right to eye health". We are committed to the bright cause of all humanity, adhere to the principle of "patient-centered", and pursue the harmonious unity of social responsibility and personal development.Through the groundbreaking "cross subsidy" model, while providing patients with higher quality ophthalmic medical services, we comprehensively carry out blindness prevention and treatment work, devote ourselves to social welfare, help vulnerable groups, and actively unite with various sectors of society to promote the comprehensive development of China's blindness prevention and even the national eye health cause. In 2018 and 2020, he won the 10th and 11th Chinese Government Honorary Charity Awards, including the "China Charity Award", the "China Public Welfare Enterprise Award", the "Best Social Responsibility Listed Company", and the "Hunan Charity Award". At the same time, actively responding to the call of the state, as a representative enterprise of China, we took the lead in participating in public welfare activities such as the "Bright the Belt and Road Initiative" and the "Bright Mekong Initiative", which was highly praised by the organizers, the governments of recipient countries and patients, and gradually developed into a famous film of global charity activities. Aier Ophthalmology has been recognized by authoritative institutions as one of the "Top 10 Most Respected Listed Companies in China" for many consecutive years, and has won the "Huapu Award" at the China Brand Festival. It has also won multiple awards such as the "Best Continuous Investment Value Award", the "Best Shareholder Return Award for Listed Companies in China", and the "Industrial Contribution Award for Listed Companies in China". It has been successfully selected as a component of the Shanghai and Shenzhen 300 Index and the MSCI China Large Cap Index.
Headquarter Changsha
Establish Date 1/24/2003
Listed Code 300015.SZ
Listed Date 10/30/2009
Chairman Chen Bang.
CEO Li Li.

Buy Premium Now

$15/month billed now

View the full stack of insights immediately

Or 7 Days Free Charge for Trial

See feature available in the Trial and Premium

See our Solution and Servicetrial.solutionservice.trial

See our Uniquness and Value deliveringtrial.solutionservice.trial